As a physician-scientist, Wondisford’s well-funded research program focuses on pituitary and pancreatic hormonal growth and regulation. He is the inventor of the approach to synthesize recombinant human TSH, for which he holds two U.S. patents. Recombinant human TSH (Thyrogen) is FDA-approved for use in the diagnosis and treatment of patients with thyroid cancer.
Program Faculty
- Fredric E. Wondisford
- Professor
- Department: Department of Medicine
- Graduate Program(s): Cell and Developmental Biology | Microbiology and Molecular Genetics | Physiology and Integrative Biology
- Major Research Interest(s): Metabolism / Nutrition, Signaling
- Research Organism(s): Cell lines, Mice
- Phone: 1.7322359838
- Email: few11@rwjms.rutgers.edu
- Robert Wood Johnson Medical School
- Clinical Academic Building CAB
- 125 Paterson Street
- New Brunswick, NJ 08903-2681
- Key Words: Pituitary and pancreatic hormonal growth and regulation
- Lab Site URL
- News Items: Kisspeptin: A New Drug to Treat Liver Disease?
